Literature DB >> 24132234

LARGE glycans on dystroglycan function as a tunable matrix scaffold to prevent dystrophy.

Matthew M Goddeeris1, Biming Wu, David Venzke, Takako Yoshida-Moriguchi, Fumiaki Saito, Kiichiro Matsumura, Steven A Moore, Kevin P Campbell.   

Abstract

The dense glycan coat that surrounds every cell is essential for cellular development and physiological function, and it is becoming appreciated that its composition is highly dynamic. Post-translational addition of the polysaccharide repeating unit [-3-xylose-α1,3-glucuronic acid-β1-]n by like-acetylglucosaminyltransferase (LARGE) is required for the glycoprotein dystroglycan to function as a receptor for proteins in the extracellular matrix. Reductions in the amount of [-3-xylose-α1,3-glucuronic acid-β1-]n (hereafter referred to as LARGE-glycan) on dystroglycan result in heterogeneous forms of muscular dystrophy. However, neither patient nor mouse studies has revealed a clear correlation between glycosylation status and phenotype. This disparity can be attributed to our lack of knowledge of the cellular function of the LARGE-glycan repeat. Here we show that coordinated upregulation of Large and dystroglycan in differentiating mouse muscle facilitates rapid extension of LARGE-glycan repeat chains. Using synthesized LARGE-glycan repeats we show a direct correlation between LARGE-glycan extension and its binding capacity for extracellular matrix ligands. Blocking Large upregulation during muscle regeneration results in the synthesis of dystroglycan with minimal LARGE-glycan repeats in association with a less compact basement membrane, immature neuromuscular junctions and dysfunctional muscle predisposed to dystrophy. This was consistent with the finding that patients with increased clinical severity of disease have fewer LARGE-glycan repeats. Our results reveal that the LARGE-glycan of dystroglycan serves as a tunable extracellular matrix protein scaffold, the extension of which is required for normal skeletal muscle function.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24132234      PMCID: PMC3891507          DOI: 10.1038/nature12605

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  46 in total

1.  Epitopes in the interacting regions of beta-dystroglycan (PPxY motif) and dystrophin (WW domain).

Authors:  A V Pereboev; N Ahmed; N thi Man; G E Morris
Journal:  Biochim Biophys Acta       Date:  2001-07-02

2.  Characterization of POMT2, a novel member of the PMT protein O-mannosyltransferase family specifically localized to the acrosome of mammalian spermatids.

Authors:  Tobias Willer; Werner Amselgruber; Rainer Deutzmann; Sabine Strahl
Journal:  Glycobiology       Date:  2002-11       Impact factor: 4.313

3.  Neural regulation of alpha-dystroglycan biosynthesis and glycosylation in skeletal muscle.

Authors:  A Leschziner; H Moukhles; M Lindenbaum; S H Gee; J Butterworth; K P Campbell; S Carbonetto
Journal:  J Neurochem       Date:  2000-01       Impact factor: 5.372

4.  Mutations in the fukutin-related protein gene (FKRP) cause a form of congenital muscular dystrophy with secondary laminin alpha2 deficiency and abnormal glycosylation of alpha-dystroglycan.

Authors:  M Brockington; D J Blake; P Prandini; S C Brown; S Torelli; M A Benson; C P Ponting; B Estournet; N B Romero; E Mercuri; T Voit; C A Sewry; P Guicheney; F Muntoni
Journal:  Am J Hum Genet       Date:  2001-10-08       Impact factor: 11.025

5.  Muscular dystrophy and neuronal migration disorder caused by mutations in a glycosyltransferase, POMGnT1.

Authors:  A Yoshida; K Kobayashi; H Manya; K Taniguchi; H Kano; M Mizuno; T Inazu; H Mitsuhashi; S Takahashi; M Takeuchi; R Herrmann; V Straub; B Talim; T Voit; H Topaloglu; T Toda; T Endo
Journal:  Dev Cell       Date:  2001-11       Impact factor: 12.270

6.  Disruption of DAG1 in differentiated skeletal muscle reveals a role for dystroglycan in muscle regeneration.

Authors:  Ronald D Cohn; Michael D Henry; Daniel E Michele; Rita Barresi; Fumiaki Saito; Steven A Moore; Jason D Flanagan; Mark W Skwarchuk; Michael E Robbins; Jerry R Mendell; Roger A Williamson; Kevin P Campbell
Journal:  Cell       Date:  2002-09-06       Impact factor: 41.582

7.  Post-translational disruption of dystroglycan-ligand interactions in congenital muscular dystrophies.

Authors:  Daniel E Michele; Rita Barresi; Motoi Kanagawa; Fumiaki Saito; Ronald D Cohn; Jakob S Satz; James Dollar; Ichizo Nishino; Richard I Kelley; Hannu Somer; Volker Straub; Katherine D Mathews; Steven A Moore; Kevin P Campbell
Journal:  Nature       Date:  2002-07-25       Impact factor: 49.962

Review 8.  O-mannosyl glycans: from yeast to novel associations with human disease.

Authors:  Tobias Willer; M Carmen Valero; Widmar Tanner; Jesus Cruces; Sabine Strahl
Journal:  Curr Opin Struct Biol       Date:  2003-10       Impact factor: 6.809

9.  Mutations in the human LARGE gene cause MDC1D, a novel form of congenital muscular dystrophy with severe mental retardation and abnormal glycosylation of alpha-dystroglycan.

Authors:  Cheryl Longman; Martin Brockington; Silvia Torelli; Cecilia Jimenez-Mallebrera; Colin Kennedy; Nofal Khalil; Lucy Feng; Ravindra K Saran; Thomas Voit; Luciano Merlini; Caroline A Sewry; Susan C Brown; Francesco Muntoni
Journal:  Hum Mol Genet       Date:  2003-09-09       Impact factor: 6.150

10.  Mouse fukutin deletion impairs dystroglycan processing and recapitulates muscular dystrophy.

Authors:  Aaron M Beedle; Amy J Turner; Yoshiaki Saito; John D Lueck; Steven J Foltz; Marisa J Fortunato; Patricia M Nienaber; Kevin P Campbell
Journal:  J Clin Invest       Date:  2012-08-27       Impact factor: 14.808

View more
  53 in total

Review 1.  Laminin G-like domains: dystroglycan-specific lectins.

Authors:  Erhard Hohenester
Journal:  Curr Opin Struct Biol       Date:  2018-12-06       Impact factor: 6.809

2.  Dystroglycan mediates homeostatic synaptic plasticity at GABAergic synapses.

Authors:  Horia Pribiag; Huashan Peng; Waris Ali Shah; David Stellwagen; Salvatore Carbonetto
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-21       Impact factor: 11.205

Review 3.  Lassa Virus Cell Entry Reveals New Aspects of Virus-Host Cell Interaction.

Authors:  Giulia Torriani; Clara Galan-Navarro; Stefan Kunz
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

Review 4.  Finding the sweet spot: assembly and glycosylation of the dystrophin-associated glycoprotein complex.

Authors:  Dewayne Townsend
Journal:  Anat Rec (Hoboken)       Date:  2014-09       Impact factor: 2.064

Review 5.  Glycan susceptibility factors in autism spectrum disorders.

Authors:  Chrissa A Dwyer; Jeffrey D Esko
Journal:  Mol Aspects Med       Date:  2016-07-11

6.  Axl Can Serve as Entry Factor for Lassa Virus Depending on the Functional Glycosylation of Dystroglycan.

Authors:  Chiara Fedeli; Giulia Torriani; Clara Galan-Navarro; Marie-Laurence Moraz; Hector Moreno; Gisa Gerold; Stefan Kunz
Journal:  J Virol       Date:  2018-02-12       Impact factor: 5.103

7.  AAV-mediated transfer of FKRP shows therapeutic efficacy in a murine model but requires control of gene expression.

Authors:  Evelyne Gicquel; Natacha Maizonnier; Steven J Foltz; William J Martin; Nathalie Bourg; Fedor Svinartchouk; Karine Charton; Aaron M Beedle; Isabelle Richard
Journal:  Hum Mol Genet       Date:  2017-05-15       Impact factor: 6.150

8.  Thrombospondin expression in myofibers stabilizes muscle membranes.

Authors:  Davy Vanhoutte; Tobias G Schips; Jennifer Q Kwong; Jennifer Davis; Andoria Tjondrokoesoemo; Matthew J Brody; Michelle A Sargent; Onur Kanisicak; Hong Yi; Quan Q Gao; Joseph E Rabinowitz; Talila Volk; Elizabeth M McNally; Jeffery D Molkentin
Journal:  Elife       Date:  2016-09-26       Impact factor: 8.140

9.  Carbohydrate-binding domain of the POMGnT1 stem region modulates O-mannosylation sites of α-dystroglycan.

Authors:  Naoyuki Kuwabara; Hiroshi Manya; Takeyuki Yamada; Hiroaki Tateno; Motoi Kanagawa; Kazuhiro Kobayashi; Keiko Akasaka-Manya; Yuriko Hirose; Mamoru Mizuno; Mitsunori Ikeguchi; Tatsushi Toda; Jun Hirabayashi; Toshiya Senda; Tamao Endo; Ryuichi Kato
Journal:  Proc Natl Acad Sci U S A       Date:  2016-08-04       Impact factor: 11.205

10.  Phosphorylation within the cysteine-rich region of dystrophin enhances its association with β-dystroglycan and identifies a potential novel therapeutic target for skeletal muscle wasting.

Authors:  Kristy Swiderski; Scott A Shaffer; Byron Gallis; Guy L Odom; Andrea L Arnett; J Scott Edgar; Dale M Baum; Annabel Chee; Timur Naim; Paul Gregorevic; Kate T Murphy; James Moody; David R Goodlett; Gordon S Lynch; Jeffrey S Chamberlain
Journal:  Hum Mol Genet       Date:  2014-07-31       Impact factor: 6.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.